Business Wire

TX-SNOW-SOFTWARE

16.11.2023 15:01:58 CET | Business Wire | Press release

Share
Snow Software Unveils Snow Copilot, its First Generative AI Assistant, Built to Solve Large Challenges in IT Asset Management and FinOps

Snow Software, the global leader in technology intelligence, today previewed Snow Copilot, the first-in-a-series of Artificial Intelligence (AI) capabilities designed to solve large challenges in IT Asset Management (ITAM) and FinOps. Developed in its innovation incubator Snow Labs, Snow Copilot is an AI assistant that empowers users to ask conversational questions and receive natural language responses. At release, Snow Copilot is available for Software Asset Management (SAM) computer data in Snow Atlas with more use cases being explored over time.

Snow Labs is a multiprong innovation initiative to help organizations make better decisions and deliver positive business outcomes with Technology Intelligence, or the ability to understand and manage all technology data, via Snow Atlas. The current project focuses on using artificial intelligence to advance data insights and further explore ways to tackle multifaceted ITAM and FinOps challenges, the first offering powered by Snow AI.

“We created Snow Labs as a space for rapid experimentation and prototyping, allowing us to test emerging technologies that sat outside of our standard product roadmap,” said Steve Tait, Chief Technology Officer and EVP, Research and Development at Snow. “Artificial intelligence is a great example of a rapidly evolving, emerging technology that could allow Snow Labs to address a myriad of challenges our customers face when making sense of their technology asset data. We believe that AI will fundamentally transform the way our customers and partners interact with their data. This is just one of many ways we are working to bring our vision around Technology Intelligence to life through innovation.”

Enhancing the Value of Data with Snow

IT manages vast amounts of data but struggles to turn that data into actionable intelligence for business impact. According to a recent Snow report, 91% of IT leaders said they need to invest in tools to extract more value out of their data. This is a contributing factor in the growing visibility gap between IT and the business units they support. IT struggles to know what software and cloud services are running both within IT and across the enterprise leading to technology overspend, higher security and compliance risk, reduced ITSM data quality, and slower decision-making. Generative AI provides new toolsets for Snow to tackle the visibility gap when it comes to understanding and acting on large technology asset data sets for ITAM, SaaS management, and FinOps.

Snow Copilot, one of the first AI assistants developed to solve advanced challenges for ITAM and FinOps, leverages the Microsoft Azure OpenAI Service. It allows customers to input questions and receive insights on their computer data, such as “How many computers have been installed in the last 90 days?,” as well as explore “what if” scenarios all directly within Snow Atlas. Snow Copilot reduces the need to export data into PowerBI or Excel to get insights into advanced questions on forecasting, asset allocation, and trend identification of SAM computer data. All data remains secure in the customer environment ensuring data privacy and integrity.

Additional AI-enabled features within the Snow AI umbrella are under exploration for 2024, including:

  • Machine Learning Entitlement Ingestion: Eliminate manual, costly entitlement uploads with automated invoice processing powered by machine learning.
  • Enhanced Data Intelligence Service (DIS) dataset with OpenAI: Receive more context about the SaaS applications running in your organization with enhanced descriptions including richer details on categories, function, etc. from the Snow DIS normalization and augmentation service.
  • Fine-tuning Large Language Models (LLM) on Snow proprietary data: Make more informed and complex decisions on technology assets with personalized licensing recommendations.

These new AI capabilities will be available on Snow Atlas, the company’s Technology Intelligence platform. The platform, released in 2021, provides a more flexible and scalable foundation for continuous innovation. Snow Atlas allows organizations to bring together their ITAM, SaaS management, cloud cost and FinOps functions, providing a unified view and actionable intelligence to manage the entire IT landscape.

“The pace at which we can innovate on Snow Atlas, both in our standard product development cycles and through Snow Labs, is remarkable with more than one production release every day for the last three quarters,” said Tait. “We are entering a new era which will redefine how we work with technology, and we want to ensure organizations feel confident and prepared to embrace this monumental shift.”

Snow Copilot and other AI innovations will be available for current Snow Atlas customers who apply for the beta program. To learn more about Snow Labs and its innovation agenda, read CTO Steve Tait’s latest blog or to discover more on Snow Atlas, visit: https://www.snowsoftware.com/products/snow-atlas/.

About Snow Software

Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116093425/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye